JUN 23, 2017 11:58 AM PDT

Simple Blood Test Could Improve Colon Cancer Outcomes

WRITTEN BY: Xuan Pham

A blood test that’s been around for decades might have the potential to improve treatment for thousands of colon cancer patients.

Image credit: Pixabay.com

Colon cancer, also known as colon cancer or bowel cancer, is the third most common non-skin cancer type in the world. The cancer usually begins as small, benign lumps of cells that form polyps in the colon. Without proper removal, these polyps can turn cancerous and cause symptoms such as abdominal pain, rectal bleeding, weakness, and fatigue. According to a recent report, the incidence of colorectal cancer is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030.

Knowing the type of colon cancer profile of individual patients could make a tremendous impact in their outcomes. As such, researchers from the Mayo Clinic scoured the National Cancer Database for colon cancer information on close to 41,000 patients. They found that a biomarker, known as carcinoembryonic antigen (CEA) can help doctors reclassify stage 2 colon cancer patients from average risk to high risk.

"The decision to give a patient chemotherapy after surgery is not a light one, and physicians must weigh the risks and benefits," said Kellie Mathis, a Mayo Clinic colon and rectal surgeon, and the study’s senior author. "We are currently using the blood test to help make these difficult decisions, and we suggest other physicians do the same."

By correctly classifying stage 2 colon cancer patients as high risk, doctors are able to guide patients to more appropriate therapies. And this may mean the use of chemotherapy. The team found that for patients with high levels of CEA, the five-year survival rate was lower (66 percent) as compared to those without elevated levels of CEA (76 percent). However, those with elevated CEA and chemotherapy in conjunction with surgery seemed to have better outcomes than surgery alone.

The blood test also saves stage 2, low-risk colon cancer patients from having to endure chemotherapy treatments.

"There is no good reason for a physician to omit this blood test, and more work needs to be done to ensure that all patients receive it," said Dr. Mathis. "If a patient with a new diagnosis of stage 2 colon cancer has an elevated carcinoembryonic antigen level, physicians should consider chemotherapy in addition to surgery.”

The blood test for CEA is currently not used for the stratification of stage 2 colon cancer. Rather, this test is performed after a patient’s surgery, for monitoring purposes. But if performed at the onset, the researchers argue the results of this test would better inform physician decision on colon cancer treatment.

Additional source: Mayo Clinic

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 21, 2021
Drug Discovery & Development
Lifesaving TheraSpheres - glass microbeads can target and destroy colorectal tumors
SEP 21, 2021
Lifesaving TheraSpheres - glass microbeads can target and destroy colorectal tumors
The innovative medical device manufacturer Boston Scientific recently showed success in treating patients with ...
OCT 07, 2021
Cell & Molecular Biology
Color-Changing Slides Improve Accuracy in Cancer Diagnosis
OCT 07, 2021
Color-Changing Slides Improve Accuracy in Cancer Diagnosis
When cancer is diagnosed, a sample has to be taken from a patient, treated, and analyzed. Researchers have now modified ...
OCT 25, 2021
Cell & Molecular Biology
The Labroots 2021 Cell Biology Virtual Event Poster Winner: 5-Azacytidine Treatment & Lung Cancer
OCT 25, 2021
The Labroots 2021 Cell Biology Virtual Event Poster Winner: 5-Azacytidine Treatment & Lung Cancer
Labroots virtual events are a great place to share research and learn about others work. These events feature participan ...
NOV 11, 2021
Cancer
US Military Veterans: Cancer Risk and Cancer Research
NOV 11, 2021
US Military Veterans: Cancer Risk and Cancer Research
The US Department of Veteran’s Affairs (VA) estimates about 50,000 new cancer cases diagnosed each year. In total, ...
DEC 02, 2021
Cancer
A New Method to Enhance Immunotherapy in Mouse Tumors
DEC 02, 2021
A New Method to Enhance Immunotherapy in Mouse Tumors
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, accounting for about 90% of pancre ...
DEC 27, 2021
Cancer
Improving Immunotherapy with a Novel Nanoparticle
DEC 27, 2021
Improving Immunotherapy with a Novel Nanoparticle
Malignant pleural effusion (MPE) occurs in cancer patients experiencing a buildup of fluid and tumor cells in the pleura ...
Loading Comments...